Importance Although the efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …

Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in
the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations …

Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …

EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib changed
dramatically the history of metastatic non-small cell lung cancer (NSCLC) harbouring EGFR …

Purpose The efficacy of gefitinib [an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor] in elderly patients with non-small cell lung cancer (NSCLC) and EGFR …

BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Introduction: Recent studies have demonstrated that first-line treatment with gefitinib, an
epidermal growth factor receptor (EFGR)–targeted tyrosine kinase inhibitor, is significantly …

Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …